NCT06850727View on ClinicalTrials.gov

Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

November 30, 2026

Conditions
Ulcerative Colitis (UC)UC - Ulcerative Colitis
Interventions
DRUG

OD-07656

Experimental intervention

DRUG

Vedolizumab

Active standard of care comparator

Trial Locations (4)

3004

RECRUITING

Alfred Health, Melbourne

3200

RECRUITING

PCRN Waikato, Hamilton

Md-2025

RECRUITING

IMSP Spitalul Clinic Republican Timofei Moneaga, Chisinau

0622

RECRUITING

PCRN Auckland, Auckland

Sponsors
All Listed Sponsors
lead

Odyssey Therapeutics

INDUSTRY

NCT06850727 - Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter